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Abstract
Background: Mixed, polyclonal Mycobacterium tuberculosis infection occurs in natural populations. Developing an
effective method for detecting such cases is important in measuring the success of treatment and reconstruction of
transmission between patients. Using whole genome sequence (WGS) data, we assess two methods for detecting
mixed infection: (i) a combination of the number of heterozygous sites and the proportion of heterozygous sites to
total SNPs, and (ii) Bayesian model-based clustering of allele frequencies from sequencing reads at heterozygous sites.
Results: In silico and in vitro artificially mixed and known pure M. tuberculosis samples were analysed to determine the
specificity and sensitivity of each method. We found that both approaches were effective in distinguishing between
pure strains and mixed infection where there was relatively high (> 10%) proportion of a minor strain in the mixture. A
large dataset of clinical isolates (n = 1963) from the Karonga Prevention Study in Northern Malawi was tested to
examine correlations with patient characteristics and outcomes with mixed infection. The frequency of mixed infection
in the population was found to be around 10%, with an association with year of diagnosis, but no association with
age, sex, HIV status or previous tuberculosis.
Conclusions: Mixed Mycobacterium tuberculosis infection was identified in silico using whole genome sequence data.
The methods presented here can be applied to population-wide analyses of tuberculosis to estimate the frequency of
mixed infection, and to identify individual cases of mixed infections. These cases are important when considering the
evolution and transmission of the disease, and in patient treatment.
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Background
The innovation of whole genome sequencing (WGS) has
brought about significant developments in our under-
standing of bacterial disease dynamics, including the
population-level transmission of pathogens and the
spread of antimicrobial resistance [1–3]. Typically, stud-
ies consider a single consensus genome to be representa-
tive of an infection. Often variation between pathogens
is determined by the comparison of genetic variants,
such as single nucleotide polymorphisms (SNPs).
However, analysis of these variants can identify more
than one allele present at a single locus, resulting in a
heterozygous base call in haploid bacterial genomes.
These sites are usually excluded from further analysis:
they can represent sequencing errors, but heterozygous
calls may be biologically relevant and indicate the pres-
ence of mixed infection [4–6].
Mixed infection occurs when two or more strains of
the same species of pathogen are present in an individ-
ual host at any one time. Strain heterogeneity arises
from transmission from multiple sources to a recipient
and is distinct from clonal evolution within the host [4].
A failure to identify the entire within-host pathogen di-
versity can impact treatment and clinical outcomes, with
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undetected strains potentially possessing key phenotypic
differences such as antibiotic resistance and virulence
[4], or being misinterpreted as reinfections rather than
relapses. Additionally, attempts to reconstruct the trans-
mission of bacterial pathogens can be complicated as
only one strain of a mixed infection may be represented
and true transmission links may not be established [5].
Polyclonal, mixed M. tuberculosis infections occur in
natural populations and have been linked to high inci-
dence populations with an elevated chance of exposure
[6–9]. Previous attempts to determine the presence of
mixed M. tuberculosis infections have primarily focused on
polymerase chain reaction (PCR) based techniques such as
IS6110 restriction fragment length polymorphism (RFLP)
and MIRU-VNTR to look for heterogeneity at diagnostic
loci [7–11]. These approaches, though, can only detect
strains that are relatively distant genetically and require a
high proportion of minor variants in the sample [12].
Strain heterogeneity has also been studied between sin-
gle colonies grown from single sputum samples [11, 13].
Culturing can reduce the number of strains identified
through differential survival through serial rounds of cul-
ture and subsequent growth on solid media [6, 14]. Add-
itionally, taking single samples from one site will not
account for potential strain heterogeneity across different
sites, which has been revealed through sequencing strains
from multiple biopsies in the lung [15]. Phylogenetic ap-
proaches revealing multiple divergent paths of heteroge-
neous SNPs have been more successful at detecting mixed
M. tuberculosis infections [16], though this method can be
limited by the robustness of evolutionary tree and ances-
tral state reconstruction. A maximum-likelihood approach
has been employed in one study using the allele frequency
at mixed sites in whole genome sequences of Clostridium
difficile [4]. This method was effective at identifying
two-strain mixed infections determined using a previously
characterised database of haplotypes.
We aim to develop a simple method for detecting
non-clonal mixed infections of M. tuberculosis and esti-
mate mixture proportions from whole genome sequence
data alone. We use a test dataset of 48 in vitro and 168
in silico artificial mixtures in known proportions to de-
velop an approach for identifying mixed samples and de-
termining mixture proportions from whole genome
sequencing data. These methods are refined and tested
further using replicate tuberculosis (TB) samples from
Portugal and five replicate H37Rv reference strain sam-
ples. Finally, we apply the resulting methods to an exten-
sive clinical set of 1963 M. tuberculosis strains isolated
from patients in Malawi, a high-burden TB +HIV setting
[17], with a high TB incidence [18, 19]. In this setting we
assess the prevalence of mixed infection in an unselected
population, and examine correlations with patient char-
acteristics and outcomes.
Methods
Sample preparation and sequencing
Over 2000 Mycobacterium tuberculosis samples were ob-
tained from TB patients recruited as part of the Karonga
Prevention Study in northern Malawi, which has been
conducting research on mycobacterial infections in the
region since the 1980s. Patients exhibiting symptoms of
TB are reviewed by project staff at the district hospital
and local health centres, with those diagnosed with the
disease interviewed to obtain further patient details. In-
formation collected includes sex, age, HIV status and
contact with prior cases. A minimum of three sputum
samples were taken from each patient. The studies were
approved by the Health Sciences Research Committee in
Malawi and by the London School of Hygiene and Trop-
ical medicine ethics committee. HIV testing included
pre- and post-test counselling and informed consent.
Written consent was sought and obtained for all studies.
Whole genome sequencing was carried out on DNA ex-
tracted using extraction kits from a sweep of multiple
colonies from solid cultures for all Malawi samples using
the Illumina HiSeq 2000 platform generating 100
base-pair paired-end reads. After sequencing and quality
control, 1963 whole genome sequences were available
for analysis.
Forty-eight mixed M. tuberculosis samples were artifi-
cially generated in vitro by combining DNA from two
clinical cultures of M. tuberculosis from the Malawi pa-
tients. The DNA is quantified through spectrophotometry
in liquid culture and mixed in the appropriate volume to
produce mixed samples with the majority/minority strain
proportions 0.70/0.30, 0.90/0.10, 0.95/0.05, and 1.00/0.00,
before sequencing on the Illumina HiSeq 2000 platform
(Table 1). The paired strains encompassed both between-
and within-lineage mixes covering the four major ancient
and contemporary lineages, 1–4, in M. tuberculosis, in-
cluding Beijing strain-types (lineage 2).
PortugueseM. tuberculosis clinical isolates were sourced
from ten patients with known drug-resistant TB admitted
to four different hospitals in Lisbon between 2007 and
2013, with written consent obtained. All clinical strains
and the reference strain H37Rv (ATCC 25618D-9, Lot #
60986340) and their replicates were prepared by inoculat-
ing a single colony into Middlebrook 7H9 broth supple-
mented with 10% OADC (Oleic Albumin Dextrose
Catalase) (Becton Dickinson). Cultures underwent whole
genome sequencing using MiSeq technology (as described
in Phelan et al. [20]).
Variant calling
Sequenced reads were quality checked using FastQC and
trimmed to remove adapter sequences and low quality
reads using trimmomatic [21]. Reads were mapped to
the H37Rv reference strain (Genbank no.: NC_000962.3)
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using BWA-mem [22]. Variant calling was conducted
using SAMtools and BCFtools [23], with low quality vari-
ants (Phred score Q < 20, combined depth DP < 10) re-
moved and heterozygous calls enabled. Additionally,
variants were removed from the analysis if there was no
call (either through non-alignment of reads or low
coverage) in > 10% of individuals.
In silico simulated mixed infections
A dataset of 168 artificial M. tuberculosis mixtures were
produced in silico by simulating whole genome se-
quences in the FASTQ format from consensus se-
quences of eight Malawi clinically derived samples, two
from each lineage 1–4, using DWGSIM software [24].
The sequencing error rate was set as 0.0026 for forward
reads and 0.0040 for reverse reads reflecting the true
error rates of Illumina HiSeq sequencing [25] and the
average genome-wide substitution rate set as 1 × 10− 7.
Sequence files were combined to produce mixed samples
with the majority/minority strain proportions 0.70/0.30,
0.90/0.10, 0.95/0.05 of both between- and within-lineage
mixes and mean coverage of 100× across the genome
(Additional file 1).
Characterising heterozygous base calls
Heterozygous base calls were considered informative for
determining mixed infections. In mixed infection sam-
ples, mapped sequences at these sites will be a combin-
ation of reads from one strain carrying a SNP at this
position and reads from one or more additional strains
that do not, resulting in more than one allele call. While
the presence of these heterozygous base calls can be in-
dicative of strain mixing, these calls can also be present
in the variant output of non-mixed clonal samples at
sites under strong selection, or in regions of high vari-
ability. SNPs in pe/ppe gene regions and known anti-
biotic resistance determining genes were excluded from
the analysis to remove sites that are more likely to result
in heterozygous calls in non-mixed populations. Further-
more, to distinguish between clonal heterogeneity and
true mixed infections, only samples with > 10 heterozy-
gous sites will be considered potential mixed infections
in further analysis. This estimate has been calculated in
previous work with the Malawi samples, with up to 10
SNPs present between individuals in chains of transmis-
sion or found within individuals evolving over time [26].
Detecting mixed infection using the heterozygous base calls
The first approach to detect mixed infection used the
number of heterozygous base calls across the genome to
set a minimum threshold for distinguishing mixtures (de-
noted as the “heterozygous sites method”). In samples that
were close to the determined threshold, we included a
measure of the proportion of heterozygous calls to total
SNPs to further distinguish between mixed and pure sam-
ples. This approach will help to correctly identify pure
samples that have a relatively high level of variation across
the genome. This simple method allows for rapid identifi-
cation of potential mixtures in large datasets without re-
quiring the more complex interrogation of the sequence
reads to calculate allele frequencies at heterozygous sites.
The threshold at which samples were considered mixtures
was determined using the in vitro mixed samples, the ana-
lysis of which was blind to the known mixture proportion
of each sample, to determine whether an effective cut-off
could be established from variant calling alone.
Detecting mixed infection with Bayesian model-based
clustering
An alternative approach for detecting mixed infection was
employed that estimated the number of strains present in
a sample through Bayesian model-based clustering of
allele frequencies at heterozygous sites, implemented
through the mclust package in R [27]. A Bayesian model
was employed to minimise the impact of outlier data
points that can affect the direction and classification of
clustering groups when using other methods such as prin-
cipal component analysis (PCA) [28]. For each sample, the
major and minor allele frequencies of mapped reads at
each heterozygous base call was calculated (removing
reads where the base call has low sequence quality (Phred
P_error > 0.05)) and used as a univariate input for cluster-
ing. The allele frequencies of heterozygous sites in mixed
infection samples will cluster at similar frequencies in a
set number of groups depending on the number and pro-
portion of strains present. On the other hand, the allele
frequencies of heterozygous sites in pure samples, though
there may be a high number of heterozygous sites in sam-
ples with high clonal heterogeneity, will be more randomly
distributed without clustering. These differences are illus-
trated in Fig. 1.
Our model aimed to determine if the allele frequencies
of heterozygous sites in a sample can be optimally clus-
tered into groups relating to mixed infections of two
strains, or if the sample is a non-mixed, pure strain.
Though our methods were developed for identifying
mixed samples of two strains, the model can, in theory,
be extended to search for higher numbers of strains in a
mixture. The Mclust function in the mclust package in R
works to determine the likelihood of the data coming
from a distribution with a set number of clusters, or
mixture components, specified as G. The probability of
each observation coming from a mixture component is
modelled by a Gaussian distribution, with each group
described by the mean and unequal, scalar variance. The
likelihood of G was assessed through the Bayesian infor-
mation criterion (BIC) value of model selection. Under-
lying model calculations are shown elsewhere [27].
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The model was applied to all samples to identify the
optimal number of clustering groups (G = 2 is character-
istic of two-strain mixed infections), with the model like-
lihood assessed through the resulting BIC value. A
sample is classified as being a mixed infection of two
strains (G = 2) where, (i) the number of heterozygous
sites is > 10, and (ii) the BIC value of G = 2 is > 20. The
BIC value threshold for G = 2 was obtained from analys-
ing the artificially mixed in vitro samples and is ex-
plained in more detail in the Results section of this
paper. This method could be extended to identify mixed
infections of more than two strains where the optimal
number of found to be greater than two, though none of
our data fulfilled this criterion. Samples were classified
as likely containing a single strain (unmixed) where, (i)
the number of heterozygous sites is ≤10 or (ii) the num-
ber of heterozygous sites is > 10 but the BIC value for G
= 2 was lower than the threshold.
Results
In vitro artificially mixed M. Tuberculosis samples
Table 1 shows the sample information for each artificial
mixture along with the results of both mixture detection
approaches, arranged by the known major strain propor-
tion and then by the number of heterozygous sites.
For the heterozygous sites method, a clear threshold
that discriminates between mixed samples and pure
strains was not attained with our analysis, though with a
heterozygous SNP threshold of ≥20 sites, all but one sam-
ples with a major proportion of 0.70 (12/12) and 0.90 (11/
12) were correctly classifies as mixed, and all non-mixed
samples as pure (12/12). Introducing an additional condi-
tion of > 1.5% heterozygous to total SNP proportion for
samples containing between 11 and 19 heterozygous sites
correctly identifies the 0.90 major proportion sample with
less than 20 heterozygous sites (ERR221649) as a mixed
infection, with still no pure samples incorrectly classified.
Fig. 1 Heterozygous SNP plots for two clinical Malawi samples, illustrating the difference between clonal heterogeneity (a) and the signals of
mixed infections (b). The x-axis represents contiguous SNPs across the genome (numbered sequentially) with heterozygous SNP calls, and the
y-axis represents the proportion of non-reference alleles at that SNP. a shows no evidence of mixed infection, with read frequencies at
heterozygous sites randomly distributed between 0 and 1. b demonstrates the characteristic pattern of mixed infection with two different strains,
with the read frequencies clustering into two distinct clusters with means around 0.90 and 0.10, implying a 0.9/0.1 mixture
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Mixtures of 0.95/0.05 were more difficult to discriminate
from non-mixtures, with only 9/12 mixed samples correctly
identified using the combined thresholds of i) ≥ 20 hetero-
zygous sites and ii) > 1.5% heterozygous sites to total SNP
proportion in samples with 11–19 heterozygous sites. The
number of heterozygous varied considerably within these
mixes between 609 and 6 sites. One 0.95/0.05 sample had a
heterozygous proportion over 1.5% but contained only 6
heterozygous sites so was indistinguishable from clonal
variation. Eleven of the twelve pure strains had a heterozy-
gous proportion under 1.5%, with the other pure sample
identified as non-mixed through the low number of hetero-
zygous sites (4 SNPs). Thus, this method correctly identifies
33/36 mixed infections with no false positive results.
Identifying in vitro mixtures through Bayesian model-
based clustering
The number of strains identified in each artificial mix-
ture sample through Bayesian model-based clustering of
heterozygous SNP read proportions is shown in Table 1.
A BIC value of 20 was chosen as the maximum thresh-
old for pure strains as this value identified all unmixed
samples, and determined the highest number of mixed
samples. All samples with a major proportion of 0.70
(12/12) and all but one with a major proportion of 0.90
(11/12) were correctly classified as containing two differ-
ent strains, with all non-mixture samples identified as
containing a single strain. The identification of mixtures
in samples with 0.95 majority strain is again more diffi-
cult, with 8/12 samples misidentified as pure strains. In
total, 9/36 mixed samples were misidentified as pure
strains using this approach, performing worse than the
heterozygous sites method (3/36 mixed samples mis-
identified). Closer inspection of these samples showed
that there was no clear separation in allele frequencies at
heterozygous sites, illustrated in Fig. 1, so they could not
be delineated from pure strains. The allele frequencies at
heterozygous sites in these samples are shown in Fig. 2.
The Bayesian mixture method also allows for an
estimation of the mixing proportions of samples iden-
tified as mixed infection. All correctly classified mixed
samples were found to contain two strains, with the
mean of the uppermost cluster (closest to 1) a rea-
sonable approximation of the majority strain propor-
tion (Fig. 3). Differences in the estimated majority
strain proportion to known mixture proportion
ranged from 3.9–11.6% difference in mixtures with a
0.95 majority strain, 3.1–5.1% in mixtures with a 0.90
majority strain, and 0.08–6.0% in mixtures with a
0.70 majority strain.
Fig. 2 The plotted allele frequencies of reads at heterozygous sites in samples misidentified as pure strains in artificial mixtures of two strains
using the Bayesian model-based clustering approach. The majority/minority strain proportions are 0.90 and 0.10 in sample ERR221649 and 0.95
and 0.05 in the remaining samples). The characteristic pattern of mixed infection that would be expected in samples of more than two
non-clonal strains, e.g. Fig 1b, is not clear
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Identifying mixed infection in replicate samples
The robustness of the mixture detection methodologies
employed in this work were inspected using replicate
samples (Additional file 1). The dataset comprised one
set of five biological replicates of the H37Rv reference
strain and seven sets of three biological replicates of
clinical Portuguese M. tuberculosis isolates. In addition,
there were three sets of Portuguese TB isolates with six
technical replicates and two further biological replicates.
Using the heterozygous sites method with a threshold of
≥20 sites, we identified four Portuguese samples as mixed
infection, three biological replicates of the same sample
(Por10, 14–19 heterozygous sites, heterozygous-total
proportion between 1.6–2.2%) and one biological replicate
of Por7 (14 heterozygous sites, heterozygous-total propor-
tion 1.8%), with other Por7 replicates identified as pure
strains. All replicate samples were identified as pure
strains using the Bayesian clustering approach, including
the four samples deemed mixed infection using the het-
erozygous sites method.
A table showing the sensitivity and specificity of both
the heterozygous sites and Bayesian clustering ap-
proaches with the artificial mixture and replicate sam-
ples is shown in Table 2. At present, there is no gold
standard test for detecting mixed infection in M. tuber-
culosis from WGS data. Therefore, true positives were
Fig. 3 A comparison of the major strain proportion estimated through Bayesian model- based clustering (blue) against the known majority strain
proportion (red) in all in vitro artificial mixture samples (N = 48). The standard deviation of allele frequencies of heterozygous sites around the
mean of the estimated major proportion is shown by the error bars in black
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taken as the artificially mixed Malawi samples that were
known to be mixed infections (major strain proportion
of 0.7, 0.9 and 0.95 in Table 1), and the true negative
samples as the pure Malawi strains (major strain propor-
tion 1.0 in Table 1), and all H37Rv and Portuguese M.
tuberculosis replicate samples. The heterozygous sites
method had a higher sensitivity than the Bayesian clus-
tering method in detecting the true positive rate of
mixed infections from the artificially mixed samples
(91.7 to 75.0%); whereas the specificity of the Bayesian
clustering method was the highest for identifying un-
mixed, pure samples (100% Bayesian to 93.5% heterozy-
gous sites method).
In silico artificial mixtures
A final evaluation of both the heterozygous sites and
Bayesian clustering methods was carried out using to 168
in silico mixed samples (and the pure parental strains) with
a priori known mixture proportions of 0.70/0.30, 0.90/0.10
and 0.95/0.05 (Additional file 1). All samples in the 0.70/
30 proportion (56/56) and 96% of the 0.90/0.10 proportion
(54/56) mixtures were correctly identified (Fig. 4). The
mean majority strain proportion estimated using the
Bayesian clustering method was 0.70 (SD 0.05) and 0.83
(SD 0.04) for the 0.70/0.30 and 0.90/0.10 mixtures respect-
ively. The two 0.90 majority strain mixed samples that
were not correctly identified were within-lineage mixes,
one each of lineages 3 and 4, with only 8 and 2 heterozy-
gous sites identified. None of the 0.95/0.05 mixed samples
were identified as mixtures due to the low numbers of het-
erozygous sites found in these samples (between 0 and 2
sites in all samples) (Additional file 1).
Malawi clinically-derived isolates
A clinical dataset comprising 1963 whole genome se-
quences from Malawi patients (one sample per infected
host) covering lineages 1–4, as well as 5 M. bovis sam-
ples were then used to assess the prevalence of mixed
infection in this population. Both the heterozygous sites
and Bayesian clustering approaches were applied to this
dataset to identify isolates likely to be mixed infection.
There was high concordance between the number of
mixed infections identified with the heterozygous sites
(195/1963; 9.9%) and Bayesian clustering methods (186/
1963; 9.5%) (Additional file 1). With the heterozygous
proportion approach, all clinical isolates with > 10 het-
erozygous sites also had a heterozygous proportion of >
1.5%, thus the number of heterozygous sites was the
classifying factor with these samples using this approach.
There were nine occurrences where mixed infections
were found using the heterozygous sites approach, but
samples were deemed single strains when applying the
Bayesian clustering method; no samples were identified as
mixed only by the Bayesian method. Of these nine iso-
lates, eight had 11–14 heterozygous SNPs and heterozy-
gous proportions of 1.7–3.3, and one had 69 SNPs and a
heterozygous proportion of 12.38. Figure 5a shows a fre-
quency histogram for the number of heterozygous sites
found in all samples with the classification of mixed infec-
tion or pure strain through the Bayesian clustering
method. Allele frequency of reads at heterozygous sites
plots for the nine discrepant samples are shown in Fig. 5b.
Associations with mixed infection
The association between mixed infections and demo-
graphic and disease features was investigated in the
Malawi clinical isolates, including year of collection, age
group of patient, sex of patient, HIV status, previous TB
episode, lineage, type of TB (smear +/− and pulmonary),
clinical outcome, and isoniazid and rifampicin resistance.
Results are shown in Table 3.
Of the possible risk factors assessed, only the year of col-
lection has a significant association with mixed infection of
TB strains (p = 0.009). Patients with smear-negative pul-
monary tuberculosis (SNPT) were also found to be more
likely to harbour a mixed infection than patients
smear-positive pulmonary tuberculosis.
Table 2 The sensitivity and specificity of the heterozygous sites and Bayesian model-based clustering approaches for detecting
mixed infection in artificial mixture and replicate samples. Calculations assume that the 4 technical replicates of one sample that
were classified as mixed by the heterozygous sites method came from a pure sample. True positives were taken as the known
artificially mixed Malawi samples (Table 1), and true negatives as the known pure Malawi samples (Table 1), and all H37Rv and
Portuguese replicate strains (Additional file 1)
Number of mixed samples detected
Heterozygous sites method Bayesian model-based clustering
Artificial mixed Malawi samples 33/36 27/36
Pure Malawi samples 0/12 0/12
Technical replicates 0/18 0/18
Biological replicates 4/32 0/32
Sensitivity of method 91.7% 75.0%
Specificity of method 93.5% 100%
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(SPPT) and extra-pulmonary tuberculosis (p = 0.02).
No other disease characteristics were found to be signifi-
cantly associated with mixed infection.
Discussion
We have developed methods that can be used to detect
the signals of mixed infection in M. tuberculosis from
whole genome sequence data. These methods can be
performed in silico without requiring laboratory testing,
which can often be labour intensive and costly, allowing
for a rapid exploration of large datasets. We found that
the signal from heterozygous sites alone was sufficient to
identify mixtures in both artificially mixed and
clinically-derived samples, with mixed infection confi-
dently predicted in samples with a low number of het-
erozygous sites (12 and 11 SNPs with the heterozygous
sites and Bayesian clustering approaches). Therefore,
considering variation within whole genome sequence
data allows mixed infections of closely related strains,
such as those from within the same lineage or genotype,
to be identified.
There were key differences between the heterozygous
sites and Bayesian clustering approaches that led to dif-
ferent numbers of mixed samples being reported in dif-
ferent datasets. In the artificial in vitro mixed samples,
we found that the heterozygous sites method had better
sensitivity in detecting mixed samples, with only 3/36
mixtures not identified compared to 9/36 samples mis-
identified using Bayesian clustering. The signal from the
allele frequencies of reads in these samples was indistin-
guishable from clonal heterogeneity that could be found
in pure samples and so the Bayesian clustering could not
effectively identify the characteristic patterns of mixed
infection in these samples.
In the replicate samples, the heterozygous sites method
identified four samples as mixed infection that were not
found to be mixed using the Bayesian clustering method.
All replicate samples were considered pure strains before
analysis, though all three biological replicates of one
Fig. 4 A comparison of the major strain proportion estimated through Bayesian model- based clustering against the known majority strain
proportion in the in silico two-strain mixture samples (N = 168). The between-lineage samples are shown in red while the within-lineage samples
are shown in blue. The standard deviation of allele frequencies of heterozygous sites around the mean of the estimated major proportion is
shown by the grey crosses
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Fig. 5 (See legend on next page.)
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Portuguese isolate were identified as mixed infection with
the heterozygous sites approach. The Bayesian clustering
approach did not support this classification. In these cases,
as well as with the nine samples in the clinical Malawi
dataset where there was a different classification between
detection methods, it may be that an isolate has relatively
high levels of clonal variability, resulting in false-positives
when using the heterozygous sites approach.
The Portuguese samples were either multidrug or
extensively-drug resistant and, while SNPs in known
drug resistance loci were removed from the analysis,
other associated sites that were under selection may
have been retained that appear as heterozygous sites. Al-
lele frequencies at sites under selection can be highly
variable over time and through treatment in TB infec-
tions [29]. Consequently, drug resistant samples may
have a relatively high number of heterozygous sites with
variable allele frequencies. These samples will be cor-
rectly differentiated from mixed infections where allele
frequencies at heterozygous sites will be consistent
across the genome by the Bayesian clustering method,
but may be incorrectly identified as mixed infections
with the heterozygous sites method. Multidrug resist-
ance has also been linked to increased mutation rates
and hyper-mutant strains in TB, particularly in ‘Beijing’
strains [30, 31], which may also increase levels of hetero-
geneity in clonal isolates and lead to samples incorrectly
classified as mixed infection when using the number of
heterozygous sites alone. As such, it appears that the
heterozygous sites method is more sensitive in identify-
ing mixed infection but may overestimate the number of
mixed infections in a population. The Bayesian cluster-
ing method though will have a lower sensitivity in
detecting mixed infection but a higher specificity in cor-
rectly identifying pure strains.
Samples where the minority strain proportion was very
low proved more difficult to accurately identify in both
the in vitro and in silico artificially mixed samples, and
this problem has been highlighted in previous attempts
to detect mixed infection [4, 5]. In the in vitro artificial
mixtures with a majority strain proportion of 0.95, only
9/12 could be identified as mixed infection with
heterozygous proportions, and 4/12 identified through
Bayesian clustering. The samples correctly identified as
mixtures in 0.95/0.05 ratios were either between lineage
mixes or mixtures between two strains of the highly di-
verse Beijing genotype.
No in silico artificial mixtures with a 0.05 minority
proportion were able to be identified compared to pure
strains as the number of heterozygous sites in these
samples was found to be very low (between 0 and 2 sites
across all 56 samples). Inspecting the raw alignment files
at sites that differed between the two parental strains, and
thus would be heterozygous sites, it appears as though the
signal from the minority strain was indistinguishable from
sequencing error and so were instead called as the allele
given by the majority strain. We chose to set the sequen-
cing error in these simulated genomes as relatively high,
reflecting the top estimates of Illumina HiSeq error rates,
though manual inspection of our clinically-derived KPS
samples and in vitro mixed samples showed a lower fre-
quency of sequence errors. As sequencing technologies
continue to improve and the error rate decreases, we
predict that mixed samples with lower minority allele
frequencies will be able to be identified.
Analysing 1963 clinical M. tuberculosis isolates from
the Karonga Prevention Study in Malawi with both the
heterozygous sites and Bayesian clustering methods we
found evidence of mixed infection in between 9.5–9.9%
of the population. We had previously identified a pro-
portion of mixed infections of 2.8% in this population
looking only at mixtures between LAM and Beijing
strains [6]. The incidence of mixed infection found in
Malawi is lower than has been identified in samples
from Cape Town, South Africa (19% between Beijing
and non-Beijing strains) [32], consistent with the much
higher incidence of tuberculosis in South Africa [18, 33],
with TB incidence suggested to be linked to the rate of
mixed infection [6, 7].
Additionally, the rate of mixed infection in South Africa
was estimated using RFLP and spoligotype analysis
directly from sputum, whereas our methods have used
whole genome data isolated from solid culture. Isolating
DNA directly from sputum will likely provide a more
representative sample of the full range of strains present as
culturing can result in differential selection of strains. At
present, the application of sequencing directly from spu-
tum samples has been mainly limited to the rapid identifi-
cation of M. tuberculosis from diagnostic markers, though
recent work has obtained high quality whole genome
(See figure on previous page.)
Fig. 5 A closer inspection of samples identified as pure with the Bayesian clustering approach but mixed with the heterozygous sites approach.
a A frequency histogram of heterozygous sites in Malawi samples identified as mixed infection or pure strains with the Bayesian clustering
approach. Sample ERR323056, classified as a pure strain with 69 heterozygous sites, is highlighted. b The plotted allele frequencies of reads at
heterozygous sites for samples identified as mixed using heterozygous sites approach but as pure strains with the Bayesian clustering approach,
with sample ERR323056 shown first. Although there is some evidence of the characteristic pattern of mixed infection in some samples, the signal
from heterozygous sites is insufficient to identify these strains as mixed infections
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sequence data at a suitable depth of coverage for the appli-
cation of our methods for detecting mixed infection [34].
Interestingly there were few associations identified
with the presence of mixed TB infection. The peak pro-
portion between 2000 and 2004 is consistent with the
peak incidence of TB in the district a few years earlier
[35]. Until 2010, all isolates underwent several rounds of
culture and subculture before DNA extraction. There is
no evidence of a higher proportion of mixed infections
in the post 2010 period when DNA extraction was per-
formed from the first set of cultures. An association with
smear negative TB could be a chance finding given the
multiple comparisons.
Reconstructing the transmission of all samples and
tracing contact networks would assist us to gain a better
understanding of how mixed infections are acquired.
The methods detailed here for identifying mixed infec-
tions can be extended to estimate an approximation of
the parental strain genomes in mixtures by imputing the
nucleotide base call that has come from major and
minor strains in a mixed infection at each heterozygous
site. Including these sequences in transmission recon-
struction could provide a more complete picture of the
spread of a pathogen by including transmission events
from minor frequency strains.
It may prove more challenging to confidently detect
mixed infection in organisms other than M. tubercu-
losis using the methods detailed in this paper, particu-
larly in taxa with a high rate of recombination.
Mycobacterium species are known to have very little
recombination (excluding pe/ppe genes [36]) and
strong clonal population structure [37]. One solution
is to use the levels of heterozygosity at the gene-level
or in larger genomic regions to look for the signatures
of mixed infection. We found that these characteristic
patterns of mixed infection are present in certain
Mycobacterium Regions of Difference (RDs) in some
mixed samples (Additional files 2 and 3), and so the
methodologies described here could be applied to
similar diagnostic marker regions in other taxa to esti-
mate the presence of mixed infection.
These methods can be applied to identify mixed infec-
tion and characterise strain diversity across all sites within
a host where DNA can be isolated, not limited to cultured
sputum samples. This is particularly important with the
evidence of the reduction in strain diversity from samples
taken from the upper airway of patients as compared to in
the lung, and strain heterogeneity across different sites
within the lung itself [15]. Although we have found the
rate of mixed infection in our clinical dataset of Malawian
isolates to be relatively high (around 10%), this is still
likely to be lower than the true rate of mixed infection as
only sputum samples were taken, and many were subcul-
tured. It is also possible that where samples are sequenced
Table 3 Tuberculosis disease characteristics associated with
mixed infection. Nine individuals with mixed infections based
on heterozygous sites but not with the Bayesian clustering
method were excluded
Characteristic Mixed / Total % mixed P-value
Year
1995–1999 46/539 8.5
2000–2004 82/662 12.4
2005–2009 44/506 8.7
2010–2014 14/247 5.7 0.009
Age group (years)
< 15 2/34 5.9
15–29 61/586 10.4
30–44 87/866 10.1
45+ 36/468 7.7 0.4
Sex
Female 94/995 9.5
Male 92/959 9.6 0.9
HIV status
Negative 52/636 8.2
Positive 69/754 9.2
Positive on ART 10/120 8.3 0.8
Unknown 55/444 12.4
Previous TB
No 173/1830 9.5
Yes 13/124 10.5 0.7
Lineage
1 35/314 11.2
2 14/80 17.5
3 15/212 7.1
4 122/1343 9.1
M. bovis 0/5 0.0 0.08
Type of TB
Smear + 125/1462 8.6
Smear - 53/400 13.3
Extra-pulmonary 8/92 8.7 0.02
Outcome
Completed 116/1275 9.1
Died 41/405 10.1
Lost/transferred 29/274 10.6 0.7
Isoniazid resistance
Resistant 15/130 11.5
Sensitive 169/1757 9.3 0.5
Rifampicin resistance
Resistant 2/17 11.8
Sensitive 182/1870 9.7 0.7
P values from chi-square test except for associations with rifampicin
resistance for which the Fisher exact test was used because of small
numbers; ART Antiretroviral therapy
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at a higher coverage the signal from minor strains present
in a sample will be more evident, further increasing the
number of mixed infections identified.
Conclusion
In conclusion, we have presented simple methods for
identifying mixed M. tuberculosis infections using vari-
ation in whole genome sequencing data. These analyses
can help to accurately reconstruct the evolution and
transmission of M. tuberculosis infections, or can be ap-
plied to individual cases where low frequency variants
may be considered in the treatment of the disease.
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